title: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
abstract: Although patients with thromboembolic disease frequently have family histories of thrombosis, well-defined defects such as inherited deficiencies of anticoagulant proteins are found only in a minority of cases. Based on the hypothesis that a poor anticoagulant response to activated protein C (APC) would predispose to thrombosis, a set of new coagulation assays was developed that measure the anticoagulant response in plasma to APC. A middle-aged man with a history of multiple thrombotic events was identified. The addition of APC to his plasma did not result in a normal anticoagulant response as measured by prolongation of clotting time in an activated partial thromboplastin time (APTT) assay. Four of the proband's relatives had medical histories of multiple thrombotic events, and they and several other family members responded poorly to APC in the APTT-based assay. Subnormal anticoagulant responses to APC were also found in factor IXa- and Xa-based assays. Several possible mechanisms for the observed phenomenon were ruled out, such as functional protein S deficiency, a protein C-inhibitory antibody, or a fast-acting protease inhibitor against APC. Moreover, restriction fragment-length polymorphism analysis excluded possible linkage of the underlying molecular defect to factor VIII and von Willebrand factor genes. We now describe a previously unrecognized mechanism for familial thromboembolic disease that is characterized by poor anticoagulant response to APC. This would appear to be explained best by a hypothesized inherited deficiency of a previously unrecognized cofactor to APC. As we have identified two additional, unrelated cases with thrombosis and inherited poor anticoagulant response to APC, this may constitute an important cause for familial thrombophilia.
authors.affiliation: Department of Clinical Chemistry, University of Lund, Malmö General Hospital, Sweden.
authors.forename: B
authors.initials: B
authors.lastname: Dahlbäck
authors.forename: M
authors.initials: M
authors.lastname: Carlsson
authors.forename: P J
authors.initials: PJ
authors.lastname: Svensson
mesh_terms: D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects / Q000235:genetics*; D001778:Blood Coagulation Disorders / Q000235:genetics / Q000378:metabolism*; D001780:Blood Coagulation Tests / Q000379:methods; D015949:Factor IXa / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D010375:Pedigree; D011486:Protein C / Q000378:metabolism* / Q000494:pharmacology; D013925:Thromboplastin / Q000494:pharmacology; D013927:Thrombosis / Q000235:genetics / Q000378:metabolism*
chemical_list: D011486:Protein C; D013925:Thromboplastin; D015949:Factor IXa